Skip to content 
Something strange happened on Wall Street this week. A biotech company that most investors had written off suddenly became the hottest stock in America.
On Wednesday, Moderna’s shares shot up 177% in a single day. To put that in perspective, if you’d invested money in Moderna on Tuesday, it would have nearly tripled by Wednesday evening. And the reason wasn’t hype or speculation. It was actual science.
Here’s the full story.
On August 19, 2026, Moderna’s stock closed at $174.38, up a jaw dropping 176.97% from the previous day’s close.
Trading volume exploded too. Nearly 185 million shares changed hands, about 1,819% above its three month average of 9.6 million shares.
To put that in perspective, that’s the kind of volume spike you’d expect once in a company’s lifetime, not on a random Wednesday.
And here’s the thing.
This wasn’t some meme stock pump. This was a company whose market cap jumped from $25 billion to $69 billion in a single trading session, on the back of actual clinical trial data.
So let’s break down what happened, why it mattered so much, and whether the party has legs.
The Backstory Nobody Talks About
To understand why this move was so massive, you need to understand how far Moderna had fallen.
Everyone remembers Moderna as the COVID vaccine company that made a fortune during the pandemic. What people forget is what came after. Once COVID vaccine demand dried up, Moderna’s revenues collapsed.
The company went from earning billions in operating profit to burning cash on a portfolio of vaccines nobody was rushing to buy.
The stock reflected that pain.
Moderna shares had cratered from a pandemic-era high of around $450 to below $30 by the end of 2025. Investors who’d bought at the top were sitting on losses of over 90%.
But Moderna had a plan B all along. Its mRNA technology, the same platform used to build COVID vaccines at record speed, was also being tested as a cancer treatment. And on Tuesday, that bet finally paid off.
So What Exactly Did Moderna Announce?
Moderna and its partner Merck ran a large Phase 3 trial called INTerpath-001, testing a drug called intismeran autogene (also known as mRNA-4157) alongside Merck’s blockbuster cancer drug Keytruda.
The trial enrolled 1,137 patients with Stage IIb to IV melanoma who’d had their tumors surgically removed, comparing the combination therapy against Keytruda alone, which is currently the standard treatment.
Here’s what makes intismeran different from a regular drug.
It isn’t mass produced in a factory and shipped in identical batches. Each dose is custom built for the individual patient.
Doctors take a sample of the patient’s tumor, sequence its unique mutations, and then manufacture an mRNA shot that trains the patient’s own immune system to recognize and attack those specific cancer cells. It’s essentially a vaccine, but instead of protecting you from a virus, it’s designed to hunt down your own cancer using your own genetic fingerprint.
The trial showed the combination significantly cut the risk of the melanoma coming back and reduced the risk of it spreading to distant parts of the body, compared to Keytruda alone. Crucially, the safety profile stayed consistent with earlier studies, meaning no nasty surprises on side effects.
This matters because it’s the first time a personalized mRNA cancer therapy has succeeded in a large, late stage trial. Not a small early study. A proper Phase 3 trial, the kind regulators actually take seriously before approving a drug.
Why the Market Went Absolutely Berserk
Normally, good trial data moves a biotech stock by 10 to 20%. A 177% move needs a bit more explaining.
Part of it is that this result had been years in the making, and investors had learned to be skeptical.
Earlier data on this same drug, going back to 2022, had already shown promise, cutting the risk of recurrence or death by 49% and risk of distant metastasis or death by 59% versus Keytruda alone at the five year mark in an earlier Phase 2b study.
But biotech investors have been burned before by drugs that look great in small trials and then disappoint at scale.
So the market had priced in a lot of doubt. When the bigger, more rigorous Phase 3 trial confirmed the earlier signal, that doubt evaporated overnight, and the stock repriced violently to catch up.
The other part is optionality.
This isn’t just about melanoma.
Moderna and Merck have nine separate trials running across melanoma, lung, bladder, kidney, pancreatic and gastric cancers, all using the same underlying technology.
If it works in melanoma, there’s a real chance it works across several of these cancers too. Investors weren’t just paying for one successful drug. They were paying for the possibility that Moderna has finally cracked a platform that could spin out an entire pipeline of cancer treatments. That kind of blue sky optionality is exactly the sort of thing that sends biotech stocks parabolic.
Merck, the much bigger partner in this deal, also rallied, though nowhere near as dramatically given its 4% gain against Moderna’s much larger move, simply because Keytruda is already a massive product for Merck and this is more of an add-on win rather than a make-or-break event for the company.
Even Moderna’s mRNA rival BioNTech caught a bid, closing up nearly 22% on the day, as investors bet that if personalized mRNA cancer vaccines work for Moderna, BioNTech’s similar pipeline might be worth a second look too.
But Should You Actually Be Excited?
Here’s where we put the brakes on a little.
First, the full dataset hasn’t been released yet.
What Moderna and Merck have shared so far is a topline summary.
We don’t have the actual numbers on how much the risk of recurrence dropped, we don’t have mature survival data, and we don’t have a confirmed timeline for when they’ll actually file for regulatory approval.
Wall Street analysts have flagged this too, noting that the initial release lacks effect sizes, mature survival data and a regulatory timetable.
Second, even if approved, personalized medicine is genuinely hard to scale.
Every single dose has to be manufactured individually for one specific patient, starting from that patient’s tumor sample.
That’s a fundamentally different, and far more complicated, manufacturing and logistics challenge than churning out identical vials of a normal drug. Cost, capacity and access could all become real bottlenecks.
Third, melanoma success doesn’t automatically translate to success everywhere else. Cancer is not one disease, it is hundreds of different diseases that happen to share a name. A therapy that works well in melanoma could still fail in lung or pancreatic cancer, where the biology is completely different.
And that’s exactly the kind of caution one prominent biotech analyst voiced after the news broke, assigning Moderna a Hold rating rather than a Buy, arguing investors should wait for the complete dataset and clearer regulatory visibility before getting carried away, even while acknowledging the long term upside if intismeran expands into bigger markets.
The Bigger Picture
Step back for a second, and this story is about more than just one stock’s wild trading day. It’s a genuine milestone for medicine. This is the first time a personalized mRNA cancer vaccine, built individually for each patient’s tumor, has actually worked in a proper Phase 3 trial. If this technology holds up across the other cancers currently being tested, we could be looking at a fundamentally new category of cancer treatment, one that’s tailored to your own biology rather than a one size fits all chemical.
For Moderna specifically, this is the validation the company has been chasing since the pandemic ended. It finally has proof that its mRNA platform isn’t a one trick pony that only works for infectious diseases. Whether that translates into billions of dollars of actual revenue, and whether the stock’s current $69 billion valuation is justified, is a story that will play out over the next few years, not the next few days.
For now though, Moderna shareholders who held through two brutal years of losses finally got their moment. Just don’t expect an encore performance every Wednesday.
